Kite Pharma has entered into a partnership with Daiichi Sankyo for axicabtagene ciloleucel—approved USAN for KTE-C19—in Japan. Axicabtagene ciloleucel, Kite’s lead product candidate, is an investigational therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Daiichi Sankyo will be responsible for ...